DrugPatentWatch Database Preview
CABERGOLINE Drug Profile
» See Plans and Pricing
When do Cabergoline patents expire, and when can generic versions of Cabergoline launch?
Cabergoline is a drug marketed by Actavis Labs Fl Inc, Apotex Corp, Impax Labs Inc, Ingenus Pharms Llc, Ivax Sub Teva Pharms, Mylan, and Par Pharm. and is included in seven NDAs.
The generic ingredient in CABERGOLINE is cabergoline. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cabergoline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cabergoline
A generic version of CABERGOLINE was approved as cabergoline by IVAX SUB TEVA PHARMS on March 7th, 2007.
Summary for CABERGOLINE
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 7 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 53 |
| Patent Applications: | 3,967 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CABERGOLINE |
| What excipients (inactive ingredients) are in CABERGOLINE? | CABERGOLINE excipients list |
| DailyMed Link: | CABERGOLINE at DailyMed |
Recent Clinical Trials for CABERGOLINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 2 |
| Fertility Center of Las Vegas | Phase 4 |
| Brigham and Women's Hospital | Phase 2 |
Pharmacology for CABERGOLINE
| Drug Class | Ergot Derivative |
